ASTRAZENECA PLC
No SEC Form 4 filings for $AZN in the last 30 days.
European shares edged up in cautious trade as investors weighed inflation risks and expectations of higher central-bank rates. The STOXX 600 rose 0.2% to 629.44; Germany’s DAX gained 0.6%, France’s CAC 40 added 0.5%, and the UK’s FTSE 100 was slightly higher. Automakers rose on April sales growth. Pets At Home jumped nearly 5% after improved Q4 retail sales; AstraZeneca fell as the FDA sought more time.
Flputnam Investment Management Co. increased its AstraZeneca (NYSE:AZN) stake by 3.7% in Q4, adding 12,056 shares to hold 335,558. The position was valued at about $58.89M and represented ~0.9% of its portfolio. AstraZeneca reported Q1 EPS of $2.58 and revenue of $15.29B. Other investors also adjusted holdings; institutional investors own 20.35%.
At Bloom Burton & Co.’s 2026 Healthcare Investor Conference in Toronto, Eric Tokat of Centerview Partners said life-sciences M&A is rebounding. In 2026 YTD, biopharma saw 14 deals worth US$49B, after US$112B in 2025. He cited patent expiries, rising competition, and private deals (~40% YTD), plus China licensing growth (McKinsey: 28% of top-20 pharma licensing deals in 2024 involved Chinese firms).
